Reviews in Endocrine and Metabolic Disorders

, Volume 19, Issue 3, pp 221–225 | Cite as

Transgender medicine - puberty suppression

  • Leonidas PanagiotakopoulosEmail author


Puberty suppression is the reversible first step of endocrine medical treatment in transgender youth, and allows for two very important aspects of transgender management. Firstly, it buys the patient, family and their medical team time to fully evaluate the presence and persistence of gender dysphoria. Secondly, it successfully prevents the development of cis-gender unwanted secondary sexual characteristics. The latter, when present, almost certainly increase the burden of psychological co-morbidity for any transgender person. This management is modelled from treatment of gonadotropin-dependent precious puberty, with use of GnRH agonists at its core. With the increasing number of transgender youth treated, and the changing demographics of patients seeking medical care, providers are faced with the decision to start puberty blockade at younger ages than previous decades. This article will review the rationale behind puberty blockade for transgender children, the providers’ options for achieving this goal, the emerging literature for potential adverse effects on such an approach, as well as identify directions of potential future research.


Puberty suppression Puberty blockade Transgender GnRH agonists Bone health Endocrine transgender care 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Hamburger C, Sturup GK, Dahl-Iversen E. Transvestism: Hormonal, psychiatric, and surgical treatment. J Am Med Assoc. 1953;152(5):391–6.CrossRefGoogle Scholar
  2. 2.
    Witeck B. Cultural change in acceptance of LGBT people: Lessons from social marketing. Am J Orthop. 2014;84(1):19–22.CrossRefGoogle Scholar
  3. 3.
    Kreiss JL, Patterson DL. Psychosocial issues in primary care of lesbian, gay, bisexual, and transgender youth. J Pediatr Health Care. 1997;11(6):266–74.CrossRefGoogle Scholar
  4. 4.
    Hsieh S, Leininger J. Resource list: Clinical care programs for gender-nonconforming children and adolescents. Pediatr Ann. 2014;43(6):238–44.CrossRefGoogle Scholar
  5. 5.
    Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903.CrossRefGoogle Scholar
  6. 6.
    Diagnostic and Statistical Manual of Mental Disorders, in Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Publishing; 2013.Google Scholar
  7. 7.
    Zucker KJ. On the "natural history" of gender identity disorder in children. J Am Acad Child Adolesc Psychiatry. 2008;47(12):1361–3.CrossRefGoogle Scholar
  8. 8.
    Wallien MS, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. J Am Acad Child Adolesc Psychiatry. 2008;47(12):1413–23.CrossRefGoogle Scholar
  9. 9.
    Steensma TD, Biemond R, de Boer F, Cohen-Kettenis PT. Desisting and persisting gender dysphoria after childhood: A qualitative follow-up study. Clin Child Psychol Psychiatry. 2011;16(4):499–516.CrossRefGoogle Scholar
  10. 10.
    Drummond KD, Bradley SJ, Peterson-Badali M, Zucker KJ. A follow-up study of girls with gender identity disorder. Dev Psychol. 2008;44(1):34–45.CrossRefGoogle Scholar
  11. 11.
    Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med. 2011;364(13):1251–7.CrossRefGoogle Scholar
  12. 12.
    Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291–303.CrossRefGoogle Scholar
  13. 13.
    Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13–23.CrossRefGoogle Scholar
  14. 14.
    Martinerie L, le Heuzey MF, Delorme R, Carel JC, Bargiacchi A. Assessment and management of gender dysphoria in children and adolescents. Arch Pediatr. 2016;23(6):668–73.CrossRefGoogle Scholar
  15. 15.
    Steensma TD, McGuire JK, Kreukels BPC, Beekman AJ, Cohen-Kettenis PT. Factors associated with desistence and persistence of childhood gender dysphoria: A quantitative follow-up study. J Am Acad Child Adolesc Psychiatry. 2013;52(6):582–90.CrossRefGoogle Scholar
  16. 16.
    Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, et al. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the pediatric research in office settings network. Pediatrics. 1997;99(4):505–12.CrossRefGoogle Scholar
  17. 17.
    Herman-Giddens ME, Steffes J, Harris D, Slora E, Hussey M, Dowshen SA, et al. Secondary sexual characteristics in boys: data from the pediatric research in office settings network. Pediatrics. 2012;130(5):e1058–68.CrossRefGoogle Scholar
  18. 18.
    Holt V, Skagerberg E, Dunsford M. Young people with features of gender dysphoria: demographics and associated difficulties. Clin Child Psychol Psychiatry. 2016;21(1):108–18.CrossRefGoogle Scholar
  19. 19.
    Vrouenraets LJ, et al. Perceptions of sex, gender, and puberty suppression: A qualitative analysis of transgender youth. Arch Sex Behav. 2016;45(7):1697–703.CrossRefGoogle Scholar
  20. 20.
    Mahfouda S, Moore JK, Siafarikas A, Zepf FD, Lin A. Puberty suppression in transgender children and adolescents. Lancet Diabetes Endocrinol. 2017;5(10):816–26.CrossRefGoogle Scholar
  21. 21.
    Cohen-Kettenis PT, Delemarre-van de Waal HA, Gooren LJ. The treatment of adolescent transsexuals: Changing insights. J Sex Med. 2008;5(8):1892–7.CrossRefGoogle Scholar
  22. 22.
    de Vries AL, et al. Puberty suppression in adolescents with gender identity disorder: A prospective follow-up study. J Sex Med. 2011;8(8):2276–83.CrossRefGoogle Scholar
  23. 23.
    Smith YL, et al. Sex reassignment: Outcomes and predictors of treatment for adolescent and adult transsexuals. Psychol Med. 2005;35(1):89–99.CrossRefGoogle Scholar
  24. 24.
    Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal H, Gooren LJ, Meyer WJ 3rd, Spack NP, et al. Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(9):3132–54.CrossRefGoogle Scholar
  25. 25.
    Delemarre-van de Waal HA, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: A protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol. 2006;155(suppl 1):S131–7.CrossRefGoogle Scholar
  26. 26.
    Roger M, Chaussain JL, Bost M, Bozzola M, Colle M, Despert F, et al. Treatment of precocious puberty with LH-RH agonists. Multicenter study using D-Trp-6-LH-RH in a programmed-release form. Rev Fr Gynecol Obstet. 1986;81(5):297–305.PubMedGoogle Scholar
  27. 27.
    Lee PA, Luce M, Bacher P. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation. J Pediatr Endocrinol Metab. 2016;29(11):1249–57.PubMedGoogle Scholar
  28. 28.
    Manasco PK, et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab. 1988;67(2):368–72.CrossRefGoogle Scholar
  29. 29.
    Roth C. Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Expert Opin Investig Drugs. 2002;11(9):1253–9.CrossRefGoogle Scholar
  30. 30.
    Newton CL, Anderson RC, Millar RP. Therapeutic neuroendocrine agonist and antagonist analogs of hypothalamic neuropeptides as modulators of the hypothalamic-pituitary-gonadal Axis. Endocr Dev. 2016;30:106–29.CrossRefGoogle Scholar
  31. 31.
    Stevens J, Gomez-Lobo V, Pine-Twaddell E. Insurance coverage of puberty blocker therapies for transgender youth. Pediatrics. 2015;136(6):1029–31.CrossRefGoogle Scholar
  32. 32.
    Collipp PJ, et al. Constitutional Isosexual precocious puberty. Effects of medroxyprogesterone acetate therapy. Am J Dis Child. 1964;108:399–405.CrossRefGoogle Scholar
  33. 33.
    Hahn HB Jr, Hayles AB, Albert A. Medroxyprogesterone and constitutional precocious puberty. Mayo Clin Proc. 1964;39:182–90.PubMedGoogle Scholar
  34. 34.
    Surti NR. Treatment of constitutional precocious puberty with medroxyprogesterone acetate. Proc R Soc Med. 1965;58:123–4.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Tack LJW, Heyse R, Craen M, Dhondt K, Bossche HV, Laridaen J, et al. Consecutive Cyproterone acetate and estradiol treatment in late-pubertal transgender female adolescents. J Sex Med. 2017;14(5):747–57.CrossRefGoogle Scholar
  36. 36.
    Tack LJ, et al. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: A retrospective analysis. Biol Sex Differ. 2016;7:14.CrossRefGoogle Scholar
  37. 37.
    Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012;97(5):1572–80.CrossRefGoogle Scholar
  38. 38.
    Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011;159(6):982–7. e1CrossRefGoogle Scholar
  39. 39.
    Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N, Triptorelin 3-month CPP Study Group. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2006;154(1):119–24.CrossRefGoogle Scholar
  40. 40.
    Lewis KA, Goldyn AK, West KW, Eugster EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr. 2013;163(4):1214–6.CrossRefGoogle Scholar
  41. 41.
    Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241–8.PubMedGoogle Scholar
  42. 42.
    Schagen SE, et al. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016;13(7):1125–32.CrossRefGoogle Scholar
  43. 43.
    Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: A multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697–704.CrossRefGoogle Scholar
  44. 44.
    Fuqua JS. Treatment and outcomes of precocious puberty: An update. J Clin Endocrinol Metab. 2013;98(6):2198–207.CrossRefGoogle Scholar
  45. 45.
    Sun Pharmaceutical Industries, Inc. Leuprolide acetate injection [prescribing information]. Cranbury; 2014.Google Scholar
  46. 46.
    Stojilkovic SS, Catt KJ. Novel aspects of GnRH-induced intracellular signaling and secretion in pituitary gonadotrophs. J Neuroendocrinol. 1995;7(10):739–57.CrossRefGoogle Scholar
  47. 47.
    Abbvie, Inc. Lupron Depot-PED (leuprolide) [prescribing information]. North Chicago; 2017.Google Scholar
  48. 48.
    Lee JW, Kim HJ, Choe YM, Kang HS, Kim SK, Jun YH, et al. Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty. Ann Pediatr Endocrinol Metab. 2014;19(3):135–40.CrossRefGoogle Scholar
  49. 49.
    van der Sluis IM, Boot AM, Krenning EP, Drop SLS, de Muinck Keizer-Schrama SMPF. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab. 2002;87(2):506–12.CrossRefGoogle Scholar
  50. 50.
    Guaraldi F, Beccuti G, Gori D, Ghizzoni L. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2016;174(3):R79–87.CrossRefGoogle Scholar
  51. 51.
    Nam HK, Kim HR, Rhie YJ, Lee KH. Serum anti-Mullerian hormone levels in precocious puberty girls according to stage of GnRH agonist treatment. J Korean Med Sci. 2017;32(3):475–9.CrossRefGoogle Scholar
  52. 52.
    Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese study group on central precocious puberty. J Clin Endocrinol Metab. 2005;90(3):1371–6.CrossRefGoogle Scholar
  53. 53.
    Rowlands S, Amy JJ. Preserving the reproductive potential of transgender and intersex people. Eur J Contracept Reprod Health Care. 2018;23(1):58–63.CrossRefGoogle Scholar
  54. 54.
    Saggese G, Bertelloni S, Baroncelli GI, Battini R, Franchi G. Reduction of bone density: An effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur J Pediatr. 1993;152(9):717–20.CrossRefGoogle Scholar
  55. 55.
    Neely EK, Bachrach LK, Hintz RL, Habiby RL, Slemenda CW, Feezle L, et al. Bone mineral density during treatment of central precocious puberty. J Pediatr. 1995;127(5):819–22.CrossRefGoogle Scholar
  56. 56.
    Antoniazzi F, Bertoldo F, Zamboni G, Valentini R, Sirpresi S, Cavallo L, et al. Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur J Endocrinol. 1995;133(4):412–7.CrossRefGoogle Scholar
  57. 57.
    Boot AM, de Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab. 1998;83(2):370–3.PubMedGoogle Scholar
  58. 58.
    Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: Impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93(1):190–5.CrossRefGoogle Scholar
  59. 59.
    Klink D, Caris M, Heijboer A, van Trotsenburg M, Rotteveel J. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab. 2015;100(2):E270–5.CrossRefGoogle Scholar
  60. 60.
    Vlot MC, Klink DT, den Heijer M, Blankenstein MA, Rotteveel J, Heijboer AC. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone. 2017;95:11–9.CrossRefGoogle Scholar
  61. 61.
    Fisher AD, Castellini G, Ristori J, Casale H, Giovanardi G, Carone N, et al. Who has the worst attitudes toward sexual minorities? Comparison of transphobia and homophobia levels in gender dysphoric individuals, the general population and health care providers. J Endocrinol Investig. 2017;40(3):263–73.CrossRefGoogle Scholar
  62. 62.
    Le V, et al. Types of social support and parental acceptance among transfemale youth and their impact on mental health, sexual debut, history of sex work and condomless anal intercourse. J Int AIDS Soc. 2016;19(3 Suppl 2):20781.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Zucker KJ. Epidemiology of gender dysphoria and transgender identity. Sex Health. 2017;14(5):404–11.CrossRefGoogle Scholar
  64. 64.
    Tangpricha V, Hannema SE, Irwig MS, Meyer WJ III, Safer JD, Hembree WC. 2017 American Association of Clinical Endocrinologists/Endocrine Society update on transgender medicine: case discussions. Endocr Pract. 2017;23(12):1430–6.CrossRefGoogle Scholar
  65. 65.
    Brito VN, Spinola-Castro AM, Kochi C, Kopacek C, Silva PCA, Guerra-Júnior G. Central precocious puberty: revisiting the diagnosis and therapeutic management. Arch Endocrinol Metab. 2016;60(2):163–72.CrossRefGoogle Scholar
  66. 66.
    Jarin, J, et al. Cross-Sex Hormones and Metabolic Parameters in Adolescents With Gender Dysphoria. Pediatrics. 2017;139(5).CrossRefGoogle Scholar
  67. 67.
    Schneider MA, et al. Brain maturation, Cognition and Voice Pattern in a Gender Dysphoria Case under Pubertal Suppression. Front Hum Neurosci. 2017;11:528.CrossRefGoogle Scholar
  68. 68.
    Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: A preliminary report comparing daily subcutaneous injections with monthly depot injections. Eur J Surg Oncol. 1985;11(2):159–65.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of Pediatric EndocrinologyEmory UniversityAtlantaUSA

Personalised recommendations